Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03948516 · ClinicalTrials.gov registry record
Sickle Cell Disease, Hemechip
A clinical trial, sponsored by University Hospitals Cleveland Medical Center.
- Completed
- Registry status
- 738
- Enrollment target
NCT03948516: Completed study, sponsored by University Hospitals Cleveland Medical Center.
NCT03948516 is a clinical trial that has completed, run by University Hospitals Cleveland Medical Center. The registered enrollment target is 738 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03948516 has completed, sponsored by University Hospitals Cleveland Medical Center.
- COMPLETED
- Registry status
- 738 participants
- Enrollment target
Study Summary
Sickle cell disease is very common in Nigeria. Early diagnosis is important to prevent or reduce serious complications from the disease and to enable children stay healthy. To this end, the investigators would like to test a new, simple and quick device called the HemeChip to determine if it can detect whether or not someone has sickle cell disease. The investigators will compare the results obtained with the HemeChip with a standard method of diagnosing sickle cell disease known as Isoelectric focusing (IEF) or High Performance Liquid Chromatography (HPLC).If the investigators show that the new device can differentiate between children who have sickle cell disease and those who don't as successfully as the IEF or HPLC, they estimate a sharp increase in the use of this device in many countries especially in Africa due to its lower cost
Primary Outcome
The results obtained using the HemeChip will be compared to High Performance Liquid Chromatography (HPLC), and the sensitivity and specificity of the HemeChip will be determined.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 738 participants |
| Start Date | 2017-07-11 |
| Est. Completion | 2018-04-26 |
What the finished NCT03948516 record still lists
NCT03948516 is an observational study that tracks outcomes without assigning an intervention. The registered 738 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT03948516 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03948516 about?
NCT03948516 is a clinical study titled "Sickle Cell Disease, Hemechip". Sickle cell disease is very common in Nigeria. Early diagnosis is important to prevent or reduce serious complications from the disease and to enable children stay healthy. To this end, the investigators would like to test a new, simple and quick device called the HemeChip to determine if it can det...
What is the current status of trial NCT03948516?
This trial is currently completed. The enrollment target is 738 participants. The study started on 2017-07-11. Estimated completion is 2018-04-26.
Who is sponsoring clinical trial NCT03948516?
This trial is sponsored by University Hospitals Cleveland Medical Center, which has 230 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03723928 · 739 participants · NA
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
- NCT03963622 · 740 participants · NA
Careful Ventilation in Acute Respiratory Distress Syndrome (COVID-19 and Non-COVID-19)
- NCT04074135 · 740 participants · Phase 2
Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
- NCT05215340 · 740 participants · Phase 3
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI